- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04240717
Shared Decision Making on Immunotherapy in Oncology (PEF-Immun)
Shared Decision Making on Immunotherapy in Oncology - Prospective, Randomized, Controlled Trial
Patients with advanced melanoma are confronted with a serious treatment decision. The current guideline recommends considering the option of immunotherapy with checkpoint inhibitors. The substances approved for this purpose differ greatly in their efficacy and the risk for adverse events. Besides, in about half of the patients with advanced melanoma a BRAF V600 Mutation is found. In these patients, in addition to immunotherapy, treatment with BRAF/MEK inhibitors must be considered.
Research on shared decision making suggests that patients achieve greater satisfaction with the decision if they are actively being involved in the decision-making process. To enable them to do so, an interactive, web-based patient decision aid (PtDA) informing about the treatment options for advanced melanoma will be developed and evaluated in a bicentric, prospective randomized controlled clinical trial.
The use of PtDA is expected to lead to a higher level of information about the benefits and risks of the various treatment options (primary hypothesis).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Immunotherapies are regarded as a new, promising treatment option for patients with advanced melanoma. However, immunotherapies can cause massive up to life-threatening side effects. The risks and benefits vary considerably between the possible therapy options. Besides, in about half of the patients with advanced melanoma a BRAF V600 Mutation is found. In these patients, in addition to immunotherapy, treatment with BRAF/MEK inhibitors must be considered. This treatment option usually produces a rapid response. In most cases, however, melanomas develop resistance after about 12 months.
Therefore, patients with advanced melanoma and their treating physicians are confronted with a very complex and preference-sensitive decision situation. Support in the form of a Patient Decision Aid (PtDA) can be helpful to support this complex decision-making process.
In the first project phase, an interactive web-based PtDA on treatment options for advanced melanomas will be developed. In the second phase of the project, the PtDA will be evaluated in a prospective randomized controlled clinical trial. Patients with a diagnosis of advanced melanoma will be recruited at the National Center for Tumor Diseases (NCT) Heidelberg and at the University Cancer Center (UCC) Dresden.
Patients of the intervention group will receive access to the interactive PtDA prior to a medical consultation. Patients of the control group will receive the medical consultation only (treatment-as-usual). Group differences between the intervention group and the control group are analysed at T1 (immediately after the medical consultation) and T2 (three months after the medical consultation). The following variables are measured: informedness of the decision (primary outcome), decision satisfaction, and involvement of the patients in the decision process.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Heidelberg, Baden-Württemberg, Germany, 69115
- University Hospital Heidelberg
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Carl Gustav Carus University Hospital Dresden
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of metastatic melanoma (C43), stage 3 and 4
- first-line therapy
- tumor or metastases are not resectable
- sufficient knowledge of the German language to use the PtDA
- informed written consent to participate in the study
Exclusion Criteria:
- limited legal capacity or impairments in this respect
- cognitive or physical impairments, which severely complicate the use of the Patient Decision Aid (e.g. impaired vision)
- severe psychiatric or mental illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patient Decision Aid
Patients review an interactive, web-based Patient Decision Aid regarding their treatment options.
Afterwards they receive medical consultation.
|
The Patient Decision Aid is an interactive, web-based tool that provides information on advanced melanoma and its treatment options with a strong focus on immunotherapies (i.e.
response to therapy, risk of side effects).
Other Names:
|
No Intervention: Treatment As Usual
Patients receive medical consultation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knowledge about different treatment options
Time Frame: T1 = after intervention (PtDA/TAU); duration of assessment: 10 minutes
|
Knowledge is assessed by a self-developed multiple choice test assessing knowledge about course, benefits, risks, and mechanisms of actions of different treatment options.
Higher scores indicate higher knowledge about treatment options.
|
T1 = after intervention (PtDA/TAU); duration of assessment: 10 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decision satisfaction
Time Frame: T1 = after intervention (PtDA/TAU); duration of assessment: 2 minutes
|
Decision satisfaction is assessed by the Satisfaction with Decision Scale (SwD; min.
value: 6, max.
value: 30; higher scores indicate higher satisfaction with decision)
|
T1 = after intervention (PtDA/TAU); duration of assessment: 2 minutes
|
Decision satisfaction (follow-up)
Time Frame: T2 = approx. 3 months after intervention (PtDA/TAU), before and after being informed about potential tumor progress; duration of assessment: 2 minutes
|
Decision satisfaction is assessed with the same scale used at T1 (see Outcome 2 for a detailed description)
|
T2 = approx. 3 months after intervention (PtDA/TAU), before and after being informed about potential tumor progress; duration of assessment: 2 minutes
|
Patient involvement in the decision making process
Time Frame: during medical consultation; duration of assessment: approx. 30 minutes
|
Patient involvement in the decision making process is assessed by the Observer OPTION 5 (min.
value: 0, max.
value: 20, higher scores indicate higher patient involvement in the decision making process)
|
during medical consultation; duration of assessment: approx. 30 minutes
|
Choice of treatment option
Time Frame: T1 = after the intervention (PtDA/TAU); duration of assessment: 1 minute
|
Choice of treatment option is assessed by a self-developed item
|
T1 = after the intervention (PtDA/TAU); duration of assessment: 1 minute
|
Quality of physician-patient interaction
Time Frame: T1 = after the intervention (PtDA/TAU); duration of assessment: 2 minutes
|
Quality of physician-patient interaction is assessed by the Questionnaire on the Quality of Physician-Patient Interaction (QQPPI, min.
value: 14, max.
value: 70, higher values indicate higher quality of physician-patient interaction)
|
T1 = after the intervention (PtDA/TAU); duration of assessment: 2 minutes
|
Knowledge about different treatment options (follow-up)
Time Frame: T2: approx. 3 months after intervention (PtDA/TAU), before being informed about potential tumor progress; duration of assessment: 10 minutes
|
Knowledge is assessed with the same multiple choice test used at T1 (see Outcome 1 for a detailed description).
|
T2: approx. 3 months after intervention (PtDA/TAU), before being informed about potential tumor progress; duration of assessment: 10 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christiane Bieber, Prof. Dr., Heidelberg University
Publications and helpful links
General Publications
- Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, Holmes-Rovner M, Llewellyn-Thomas H, Lyddiatt A, Thomson R, Trevena L. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017 Apr 12;4(4):CD001431. doi: 10.1002/14651858.CD001431.pub5.
- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Marquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schoffski P, Carlino MS, Lebbe C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.
- Volk RJ, Llewellyn-Thomas H, Stacey D, Elwyn G. Ten years of the International Patient Decision Aid Standards Collaboration: evolution of the core dimensions for assessing the quality of patient decision aids. BMC Med Inform Decis Mak. 2013;13 Suppl 2(Suppl 2):S1. doi: 10.1186/1472-6947-13-S2-S1. Epub 2013 Nov 29.
- Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Melanoma. Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9. Erratum In: Lancet. 2019 Feb 23;393(10173):746.
- Grabbe P, Gschwendtner KM, Maatouk I, Strobel SB, Salzmann M, Bossert J, Eich W, Wild B, Meier F, Hassel JC, Bieber C. Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. Trials. 2021 Apr 20;22(1):294. doi: 10.1186/s13063-021-05234-4.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 01VSF18047
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patient Decision Aid
-
Maastricht University Medical CenterCatharina Ziekenhuis EindhovenRecruitingActinic Keratoses | Patient Decision AidNetherlands
-
Taipei Medical UniversityCompletedShared Decision Making | Quality of Care | Patient Decision Aids | Evidence-based Medicine | Lumbar Degenerative DiseaseTaiwan
-
Adrien SchwitzguebelCompletedPatient Engagement | Decision Making | General Practitioners | Computer-assistedSwitzerland
-
Melissa BrooksUniversity of British Columbia; Nova Scotia Health Authority; Dalhousie University and other collaboratorsRecruitingAbortion in First Trimester | Abortion Early | Decision Aid | Clinical Decision-making | Abortion, TherapeuticCanada
-
University of WashingtonCompletedEnd Stage Renal Disease | Patient Engagement | Dialysis | Decision Aid | End-of-life CareUnited States
-
Moroccan Society of SurgeryCompletedDecision Making | Quality of Health Care | Patient Care Team | Neoplasms/TherapyMorocco
-
Adrien SchwitzguebelWithdrawnPatient Engagement | Decision Making | General Practitioners | Computer-assistedSwitzerland
-
China Medical University HospitalRecruitingRenal Replacement Therapy | End-stage Renal Disease | Decision Aid | Decision-makingTaiwan
-
University of PittsburghIcahn School of Medicine at Mount SinaiCompletedSurrogate Decision Maker, After Death of PatientUnited States
-
Brno University HospitalNot yet recruiting
Clinical Trials on Patient Decision Aid
-
University of UtahPatient-Centered Outcomes Research Institute; Mayo Clinic; Northwestern University and other collaboratorsActive, not recruitingAtrial FibrillationUnited States
-
University of LeedsBaxter Healthcare Corporation; National Health Service, United Kingdom; Foundation... and other collaboratorsCompletedChronic Kidney FailureUnited Kingdom
-
The Netherlands Cancer InstituteUMC Utrecht; Dutch Cancer SocietyCompletedBreast CancerNetherlands
-
Maastricht University Medical CenterCatharina Ziekenhuis EindhovenRecruitingActinic Keratoses | Patient Decision AidNetherlands
-
Laval UniversityChaire en transfert de connaissances, éducation et prévention en santé respiratoire... and other collaboratorsCompleted
-
Maastricht UniversityNot yet recruitingLung Cancer Stage I | Lung Cancer Stage IINetherlands
-
Children's Hospital of PhiladelphiaCompletedDevelopmental DelaysUnited States
-
Vejle HospitalThe Ottawa Hospital Research InstituteRecruiting
-
SingHealth PolyclinicsRecruitingHypothyroidismSingapore
-
Vejle HospitalRecruitingLung Cancer, Non-small Cell | Lung Metastases | Radiation Toxicity | Stereotactic Body Radiation Therapy | Decision Making, SharedDenmark